Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. Issue 1 (December 2016)
- Record Type:
- Journal Article
- Title:
- Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. Issue 1 (December 2016)
- Main Title:
- Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases
- Authors:
- Pokrovsky, Vadim
Kazanov, Marat
Dyakov, Ilya
Pokrovskaya, Marina
Aleksandrova, Svetlana - Abstract:
- Abstract Background E.coli type II L-asparaginase is widely used for treatment of acute lymphoblastic leukemia. However, serious side effects such as allergic or hypersensitivity reactions are common for L-asparaginase treatment. Methods for minimizing immune response on L-asparaginase treatment in human include bioengeneering of less immunogenic version of the enzyme or utilizing the homologous enzymes of different origin. To rationalize these approaches we compared immunogenicity of L-asparaginases from five bacterial organisms and performed sequence-structure analysis of the presumable epitope regions. Methods IgG and IgM immune response in C57B16 mice after immunization with Wollinella succinogenes type II (WsA), Yersinia pseudotuberculosis type II (YpA), Erwinia carotovora type II (EwA), and Rhodospirillum rubrum type I (RrA) and Escherichia coli type II (EcA) L-asparaginases was evaluated using standard ELISA method. The comparative bioinformatics analysis of structure and sequence of the bacterial L-asparaginases presumable epitope regions was performed. Results We showed different immunogenic properties of five studied L-asparaginases and confirmed the possibility of replacement of EcA with L-asparaginase from different origin as a second-line treatment. Studied L-asparaginases might be placed in the following order based on the immunogenicity level: YpA > RrA, WsA ≥ EwA > EcA. Most significant cross-immunogenicity was shown between EcA and YpA. We propose that aAbstract Background E.coli type II L-asparaginase is widely used for treatment of acute lymphoblastic leukemia. However, serious side effects such as allergic or hypersensitivity reactions are common for L-asparaginase treatment. Methods for minimizing immune response on L-asparaginase treatment in human include bioengeneering of less immunogenic version of the enzyme or utilizing the homologous enzymes of different origin. To rationalize these approaches we compared immunogenicity of L-asparaginases from five bacterial organisms and performed sequence-structure analysis of the presumable epitope regions. Methods IgG and IgM immune response in C57B16 mice after immunization with Wollinella succinogenes type II (WsA), Yersinia pseudotuberculosis type II (YpA), Erwinia carotovora type II (EwA), and Rhodospirillum rubrum type I (RrA) and Escherichia coli type II (EcA) L-asparaginases was evaluated using standard ELISA method. The comparative bioinformatics analysis of structure and sequence of the bacterial L-asparaginases presumable epitope regions was performed. Results We showed different immunogenic properties of five studied L-asparaginases and confirmed the possibility of replacement of EcA with L-asparaginase from different origin as a second-line treatment. Studied L-asparaginases might be placed in the following order based on the immunogenicity level: YpA > RrA, WsA ≥ EwA > EcA. Most significant cross-immunogenicity was shown between EcA and YpA. We propose that a long N-terminus of YpA enzyme enriched with charged aminoacids and tryptophan could be a reason of higher immunogenicity of YpA in comparison with other considered enzymes. Although the recognized structural and sequence differences in putative epitope regions among five considered L-asparaginases does not fully explain experimental observation of the immunogenicity of the enzymes, the performed analysis set the foundation for further research in this direction. Conclusions The performed studies showed different immunogenic properties of L-asparaginases and confirmed the possibility of replacement of EcA with L-asparaginase from different origin. The preferable enzymes for the second line treatment are WsA, RrA, or EwA. … (more)
- Is Part Of:
- BMC cancer. Volume 16:Issue 1(2016)
- Journal:
- BMC cancer
- Issue:
- Volume 16:Issue 1(2016)
- Issue Display:
- Volume 16, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 16
- Issue:
- 1
- Issue Sort Value:
- 2016-0016-0001-0000
- Page Start:
- 1
- Page End:
- 9
- Publication Date:
- 2016-12
- Subjects:
- L-asparaginase -- Immunogenicity -- Epitope
Cancer -- Periodicals
616.994005 - Journal URLs:
- http://www.biomedcentral.com/bmccancer/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=16 ↗
http://link.springer.com/ ↗ - DOI:
- 10.1186/s12885-016-2125-4 ↗
- Languages:
- English
- ISSNs:
- 1471-2407
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 9969.xml